2545 results about "Tumor therapy" patented technology

A federated distributed computational system enables secure biological data analysis and genomic medicine with enhanced oncological therapy capabilities. The system implements patient-specific tumor-on-a-chip analysis through microfluidic control systems and cellular heterogeneity preservation, while integrating fluorescence-enhanced diagnostics using CRISPR-LNP targeting and robotic surgical navigation. The architecture coordinates spatiotemporal analysis of gene therapy delivery through molecular imaging and immune response tracking, and implements bridge RNA integration with multi-target synchronization. Treatment selection is optimized through multi-criteria scoring and patient-specific simulation modeling. Each federated node contains a local processing unit for biological data analysis, privacy preservation protocols, and a hierarchical knowledge graph structure. The system implements cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration, enabling research institutions to collaborate on complex, large-scale biological analyses while maintaining strict data privacy controls.

A federated distributed computational system enables secure oncological therapy optimization through robotic integration. The system establishes a distributed graph architecture with secure communication channels connecting computational nodes, implementing encryption protocols for cross-institutional data exchange. Each node contains processing capabilities for fluorescence-guided imaging, uncertainty quantification, and expert knowledge integration while maintaining hierarchical knowledge graphs of oncological biomarkers, interventions, and outcomes. The system coordinates domain-specific knowledge through token-space communication and implements an advanced robotic integration system for surgical interventions using spatiotemporal tumor mapping, multi-modal fluorescence imaging, surgical robot coordination, and space-time stabilized mesh management. Key capabilities include wavelength-specific multi-modal fluorescence detection, combined epistemic and aleatoric uncertainty estimation, tensor-based data integration with adaptive dimensionality control, and light cone search for adaptive treatment optimization—all while maintaining strict privacy controls.

The invention discloses an intelligent decision-making method and device based on a knowledge retrieval multi-modal large model, and belongs to the technical field of artificial intelligence and medical data processing.The method comprises the steps that multi-modal diagnosis and treatment data of a patient are obtained and preprocessed, and corresponding feature vectors are generated; performing enhancement and cross-modal feature vector fusion on the feature vector of each modal based on an enhancement fusion model to obtain a patient personalized fusion feature vector; and performing knowledge retrieval in a tumor treatment whole-process electronic record database based on the personalized fusion feature vector, obtaining a plurality of treatment schemes under similar clinical manifestations, inputting the retrieved treatment schemes and the personalized fusion feature vector of the patient into a large language model for decision making, obtaining a personalized treatment scheme of the patient, and evaluating the risk of the personalized treatment scheme. A doctor is assisted to give an actual treatment scheme; and if the multi-mode diagnosis and treatment data of the patient is updated along with the actual treatment process, updating the personalized treatment scheme and the risk thereof so as to provide real-time dynamic assistance for a doctor.

A federated distributed computational system enables secure biological data analysis and genomic medicine through hybrid simulation capabilities. The system implements a hybrid simulation orchestrator that coordinates classical numerical simulations with machine learning models for biological system analysis, while maintaining secure cross-institutional data exchange. The architecture coordinates multi-scale spatiotemporal synchronization across computational nodes, with each node containing local processing capabilities for biological data analysis and privacy preservation protocols. The system implements cellular machinery assembly analysis, real-time patient data integration, and multi-modal image integration with spatiotemporal health data annotation. Through a distributed graph architecture, the system enables cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration with adaptive dimensionality control. The system implements real-time therapeutic response prediction through multi-modal data analysis, enabling research institutions to collaborate on complex biological analyses while maintaining strict data privacy controls.

The present invention belongs to the technical field of medicinal chemistry, and particularly relates to a pyrimidine macrocyclic compound. The compound has a good inhibitory effect on KRAS mutations, has a good inhibitory effect on the G12V mutation and other types of mutations of the KRAS gene, can be used as a general KRAS inhibitor, and can be used for the treatment of tumors driven by KRASG12V and other types of gene mutations.

The invention discloses an anti-tumor treatment adverse reaction risk early warning method and system, and relates to the technical field of medical information processing, and the method comprises the steps: obtaining the physiological index data of a patient, and obtaining a short-term risk prediction result based on the time sequence change characteristics of the physiological index data of a deep neural network; obtaining clinical feature data of the patient, constructing a susceptibility assessment model, and analyzing correlation features of the clinical feature data through the susceptibility assessment model to obtain a baseline risk assessment result; and according to the short-term risk prediction result and the baseline risk assessment result, calculating a comprehensive risk score, and when the comprehensive risk score exceeds an early warning threshold of the corresponding adverse reaction type, triggering an early warning signal. According to the method, a double-layer risk assessment system is constructed by combining instant physiological index changes and clinical features of patients, the technical problems that an existing early warning method is insufficient in consideration of individual differences of the patients and poor in early warning timeliness are solved, and the accuracy and timeliness of early warning of adverse reactions of anti-tumor treatment are improved.

The invention relates to the technical field of medical image processing and tumor treatment, and provides a tumor image boundary identification method and system fused with a fluorescence boundary, and the method comprises the steps: collecting a tumor dynamic fluorescence image sequence and breathing waveform data through a fluorescence imaging device; performing multi-scale noise suppression processing on the image sequence to generate a preprocessed image without artifacts; extracting fluorescence intensity distribution characteristics through a multi-layer characteristic weighted fusion network and generating an intensity distribution matrix; constructing a motion compensation model according to the breathing waveform data, and correcting the boundary displacement of the intensity distribution matrix; fusing the corrected fluorescence features and the tumor tissue texture features to generate an initial tumor boundary contour; iterative topological optimization is carried out on the initial boundary, and boundary discontinuity is eliminated; and mapping the optimized boundary to a space coordinate system of the laser treatment equipment, generating a boundary mapping model and updating the boundary mapping model in real time. The precision and safety of laser treatment can be improved, and damage to normal tissue is reduced.

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

Provided is a Limosilactobacillus fermentum VB216, which has the deposit number of CGMCC No. 26578 in the China General Microbiological Culture Collection Center, and has the deposit date of 20 February 2023. The Limosilactobacillus fermentum has inhibitory activities with regard to a variety of pathogenic bacteria and excellent activity for degrading arginine. The present invention can be used in the preparation of products, such as food, health-care food, medicine and feed, for preventing and / or relieving and / or treating arginine metabolism-related diseases, such as hyperarginemia, malignant tumor treatment, allergic reactions, eczema, pruritus and abdominal spasm, and has great application prospects.

The invention discloses a compound represented by a formula (1), or a tautomer, a mesomer, a raceme, an enantiomer, a diastereoisomer, or a mixture form thereof, or a pharmaceutically acceptable salt, a prodrug or a solvate thereof, the structure of the formula (1) is represented as follows: # imgabs0. Strong hydrophilic sulfonic acid inner salt and / or phosphoric acid inner salt side chains are introduced at the position of (AAA and the like)-PAB (self-destruction group), so that the druggability (including hydrophilicity and stability) of the antibody drug conjugate corresponding to the compound is greatly enhanced, the in-vivo drug removal effect is reduced, and the tumor treatment effect is improved.

The invention discloses a ginsenoside liposome. The ginsenoside liposome comprises ginsenoside, phospholipid and a surfactant, and the ginsenoside comprises protopanoxadiol or / and protopanaxatriol. The invention also discloses a preparation method of the ginsenoside liposome and application of the ginsenoside liposome in preparation of medicines, cosmetics or skin care products. According to the invention, the final desugared product of ginsenoside with the effect of treating skin toxicity reaction is prepared into the liposome, so that the membrane permeation and absorption capabilities of ginsenoside are greatly improved, the skin toxicity caused by tumor treatment can be quickly and effectively relieved, and the drug effect can be played for a long time; the invention provides a new method for treating skin toxic reaction caused by tumor treatment, and makes up for the requirements which cannot be met by the existing treatment means.

The invention discloses a digital intelligent tumor prevention and treatment management platform and management method, and relates to the technical field of intelligent medical treatment, and the method comprises the steps: collecting the multi-modal data of a patient in real time, carrying out the standardized cleaning and space-time alignment processing, and generating a space-time tagging data set; inputting the multi-modal joint feature representation into an anti-fact inference engine, simulating potential effects under intervention of different treatment schemes, calculating individual processing effects, and generating an anti-fact rehabilitation suggestion set; according to the anti-fact rehabilitation suggestion set, a dynamic causal enhancement decision model is constructed, real-time physiological data feedback of the patient is continuously received through a near-end strategy optimization algorithm, and a treatment scheme is dynamically adjusted. According to the method, through multi-modal data space-time alignment and feature fusion, in combination with a tumor biological mechanism and a machine learning algorithm, the accuracy and clinical credibility of individualized tumor treatment scheme recommendation are remarkably improved.

The invention provides a tumor electric field treatment system, tumor treatment equipment and an electrode slice quality detection method, the system comprises at least one pair of electrode slices, each electrode slice comprises a plurality of electrode units and a plurality of temperature detection units, the plurality of electrode units are divided into a plurality of row groups and a plurality of column groups, and the temperature detection units are connected with the electrode units; the grounding ends of the temperature detection units in each row group are jointly connected to a grounding pin through a control switch, and the signal ends of the temperature detection units in each column group are jointly connected to a switching unit through a dual-purpose signal line after being in short circuit with the corresponding electrode units. Thus, zone control and temperature detection signal sampling can be performed on the plurality of electrode units by using fewer conductive traces, and whether the electrode slices are damaged or qualified can be monitored based on the sampled temperature detection signals.

The invention provides a tumor electric field treatment system, an electrode plate, a tumor treatment device and a method, the system comprises at least one pair of electrode plates, a plurality of electrode units of each electrode plate are divided into a plurality of row groups and a plurality of column groups, grounding ends of temperature detection units in each column group are connected to a grounding pin through a control switch, and the grounding pin is connected with a control switch. The temperature detection units in each row group are connected in series, and the signal ends of the temperature detection units are connected to the switching unit through a dual-purpose signal line after being in short circuit with the corresponding electrode units; when the dual-purpose signal line is connected to a temperature sampling point, one or more combined temperature detection signals in the temperature detection units in the electrode slice are sampled by configuring the on-off state of the control switch; when the dual-purpose signal line is connected to the alternating power line, an alternating electric signal is applied to the electrode units of at least one row group based on the alternating power line. As such, the plurality of electrode units are zoned controlled using fewer conductive traces.

The present application relates to a multi-specific bioconjugate linker and a method for synthesizing the same, and specifically to a compound or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof. The present application also relates to a method for preparing the compound and its use in tumor treatment.

A compound represented by formula (1), or a tautomer, mesomer, racemate, enantiomer, and diastereomer thereof, or mixture form thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein the structure of formula (1) is as shown below: formula (1). According to the compound, a strong hydrophilic sulfonate inner salt and / or phosphate inner salt side chain are introduced at the position of polypeptide (VC, VA, AAA, etc.)-PAB (self-immolative group) of a linker, greatly enhancing the druggability (comprising hydrophilicity and stability) of an antibody drug conjugate corresponding to the compound, reducing the in-vivo drug clearance effect, and improving the tumor treatment effect.

The invention provides a single cell transcription reaction prediction algorithm based on cross-domain feature cross migration. Drug screening is carried out by using a deep learning technology. The algorithm combines feature decoupling, cross-domain transfer learning and linear modeling methods, and specifically comprises encoder feature decoupling, feature cross transfer, disturbance state modeling and transcriptional spectrum prediction. According to the method, cross-domain transfer learning is applied to the field of drug or gene disturbance-induced cellular response prediction for the first time, and the model is constructed by using gene transcriptional profile data. In the embodiment, the whole genome determination coefficient between the predicted drug perturbation transcriptional profile and the real transcriptional profile reaches 0.81, the differential genome determination coefficient reaches 0.62, efficient prediction of the unicellular external perturbation reaction is successfully achieved, a new thought and method are provided for the field of tumor treatment, and beneficial reference is provided for future drug research and development.

According to the precise diagnosis and treatment integrated platform and method based on the coupling model, the cavitation effect is predicted through numerical simulation, negative feedback adjustment is conducted on microbubble mediated ultrasonic treatment, and precise control over the microbubble mediated ultrasonic treatment is achieved. Acoustic parameters are adjusted in real time, it can be ensured that treatment focuses on a lesion area, damage to surrounding healthy tissue is reduced, and therefore the accuracy and safety of treatment are improved. The platform integrates cavitation detection and an acoustic feedback mechanism, the microbubble cavitation effect can be monitored in real time, and treatment parameters can be automatically adjusted. Negative feedback closed-loop control can ensure a stable cavitation state, tissue damage caused by excessive cavitation is effectively avoided, and the stability and reliability of treatment are improved. The platform simplifies the operation process of controlling acoustic parameters. A doctor can complete the whole process from treatment to monitoring on the same operation interface through the integrated platform, and convenience and efficiency of clinical operation are improved. The platform is not only suitable for tumor treatment, ablation and drug delivery, but also can be applied to multiple treatment fields such as vascular diseases and neuromodulation, and has wide clinical application prospects and market potential.

The invention discloses an anti-tumor nano material based on copper death promotion as well as a preparation method and application of the anti-tumor nano material. The anti-tumor nano material is constructed by taking PCN-Cu as a metal organic framework compound and merging Pt nano particles with stable polyvinylpyrrolidone into the PCN-Cu, and the anti-tumor nano material is named as Pt-coated PCN-Cu. Experiments prove that the Pt-coated PCN-Cu can improve the concentration of copper ions in tumor cells, promote the lipoic acylation aggregation process of mitochondrial related proteins, promote degradation and proteotoxicity reaction of Fe-S cluster proteins and induce copper death of the tumor cells. The Pt-coated PCN-Cu has the advantages of being simple in preparation process, green, economical, low in cost, capable of being produced on a large scale and the like, has a good anti-tumor effect, expands a novel treatment mode for promoting tumor cell copper death, and provides a new technical means for tumor treatment.

The invention discloses a multi-metal borate nano-particle as well as a preparation method and application thereof. The preparation method comprises the following steps: in the presence of small molecules with alkyl chains, performing high-temperature thermal decomposition on an organic metal compound or a metal salt compound precursor and organic borate in a solvent, and then centrifuging, modifying, performing ultrafiltration, dialyzing and purifying to obtain the multi-metal borate nanoparticles. The preparation method disclosed by the invention has the characteristics of mildness, high efficiency and strong controllability. The multi-metal borate nanoparticles prepared by the preparation method disclosed by the invention have the advantages of monodisperse size, relatively high magnetic property and good biocompatibility. Therefore, the prepared multi-metal borate nanoparticles not only have multi-modal imaging functions such as magnetic resonance imaging, near-infrared two-region imaging, nuclear medicine imaging and magnetic particle imaging, but also can be used for various treatment means such as magnetocaloric therapy and boron neutron capture therapy; potential advantages are realized in biomedical applications such as magnetic targeting tumor treatment and imaging contrast agents, and high practical values are realized.

The invention discloses a cationic polymer-based proteolysis targeting chimera as well as preparation and application thereof, and belongs to the fields of targeting protein degradation and nanotechnology. According to the chimera, a cationic polymer is used as a connecting arm to connect a target protein ligand and an E3 ubiquitin ligase ligand to form a ternary complex, so that efficient degradation of target protein is realized. By adjusting the ligand proportion, chimeras with different degradation efficiencies can be synthesized, and accurate regulation and control are realized. The pH-responsive nano-drug obtained by hydrolyzing the targeting chimera by using the targeting protein can respond to an acidic tumor microenvironment, specifically release the chimera, and improve the targeting property and the treatment effect of the drug. Compared with the traditional PROTACs, the compound has higher bioavailability and tumor permeation effect; the preparation method of the nano-drug is simple and easy to implement, provides possibility for preparation of high-performance nano-drugs, shows potential in preparation of anti-tumor cell drugs, provides new thoughts and methods for tumor treatment, and has important clinical application value.

The invention provides a tumor treatment effect prediction method based on multi-modal data, and relates to the field of medical artificial intelligence. The method comprises the following steps: collecting magnetic resonance image data, histopathological section images and clinical baseline data of a tumor patient and a treatment response evaluation record after neoadjuvant chemotherapy; the collected image information is preprocessed; feature extraction is carried out based on the preprocessed image information; screening a feature subset with the highest prediction value from the extracted features; constructing a radiopathomics fusion model by using the feature subset with the highest prediction value; evaluating the radiopathomics fusion model; and predicting the tumor treatment effect by using the evaluated radiopathomics fusion model. The problems that an existing tumor neoadjuvant chemotherapy (NACT) curative effect prediction method is low in accuracy, poor in generalization ability, lack of multi-modal data fusion and insufficient in model interpretability are solved.

The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and / or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.

The invention discloses a cat serum albumin combined nano antibody as well as a preparation method and application thereof, and relates to the technical field of nano antibody engineering. Wherein the amino acid sequence of the cat serum albumin binding nano antibody Nb1 is shown as SEQ.ID NO.1, and the nano antibody Nb1 not only has higher affinity to cat serum albumin, but also has better binding activity to mouse serum albumin; the polypeptide can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like in the pet treatment process.

The invention relates to the field of tumor treatment, in particular to application of a small molecule compound in preparation of a medicine for treating colorectal cancer. The AKT pathway specific inhibitor MK2206 disclosed by the invention can inhibit the proliferation of colorectal cancer, induce cell cycle arrest, induce apoptosis and enhance the sensitivity of colorectal cancer cells to oxaliplatin and 5-fluorouracil. The MK2206 is used for inhibiting the activity of an AKT pathway, so that the effects of inhibiting proliferation of colorectal cancer cells, inducing apoptosis of the colorectal cancer cells and improving the sensitivity of the colorectal cancer cells to chemotherapeutic drugs oxaliplatin and 5-fluorouracil are achieved, and the MK2206 can be used for preparing drugs for treating the colorectal cancer.

A method for generating a transducer layout for delivering tumor treating fields includes storing medical images of a subject, identifying one of the medical images as an anchor medical image, and registering computed tomography medical images with magnetic resonance imaging medical images. The method further includes segmenting abnormal tissue in the medical images from other tissue types and defining a region of interest (ROI) in the medical images. The method further includes creating a 3D model of the subject. The method further includes generating a plurality of transducer layouts for application of tumor treating fields to the subject, selecting at least two of the transducer layouts as recommended transducer layouts, presenting the recommended transducer layouts, receiving a user selection of at least one recommended transducer layout, and providing a report for the selected recommended transducer layout(s).

The present invention relates to the technical field of microorganisms. Provided are a probiotic composition and a use thereof in the preparation of a product for preventing and / or treating anti-tumor treatment-related diarrhea and other health conditions. Active ingredients of the probiotic composition comprise Bifidobacterium bifidum, Enterococcus avium, Ligilactobacillus salivarius, Limosilactobacillus fermentum, and Parabacteroides distasonis. The probiotic composition has good safety, auto-aggregation capacity, antioxidant capacity, short-chain fatty acid production capacity, in-vitro cell adhesion capacity, capacity to inhibit multiple pathogenic bacteria, and capacity to treat anti-tumor treatment-related diarrhea, etc.

The invention relates to a targeted drug delivery carrier based on mesoporous polydopamine nanoparticles and application thereof.The targeted drug delivery carrier is galactose modified mesoporous dopamine coordinated with manganese ions, lysine is adopted in the carrier synthesis step to provide an alkaline environment needed by dopamine polymerization, the polymerization process is simplified, and the drug delivery efficiency is improved. Meanwhile, lysine can be introduced into the mesoporous polydopamine; and the drug loading capacity of the carrier is improved. The carrier gathers multifunctionality of drug delivery, tumor imaging and treatment, provides a comprehensive new method for tumor treatment, and enhances individuation and precision of treatment.

The invention discloses a dual-mechanism antibacterial photosensitizer as well as a preparation method and application thereof, and relates to the technical field of biomedical photoelectric functional materials. The invention relates to a triphenylamine derivative, which can realize fluorescence imaging of bacterial or fungal infection by utilizing fluorescence characteristics, can generate active oxygen under illumination to play a photodynamic therapy role, is suitable for preparing photodynamic therapy preparations and developing antibacterial materials, and can also be applied to the fields of environment and public health and tumor treatment. The problems that an existing photosensitizer is insufficient in broad spectrum, different in fungus drug resistance mechanism, limited in single treatment effect and the like can be effectively solved, and the photosensitizer has wide application prospects.

The invention belongs to the technical field of biological medicine, and particularly relates to a manganese-doped zeolite imidazole framework and application thereof in tumor radiotherapy. According to the present invention, the new use of the manganese-doped zeolite imidazole framework as the tumor radiosensitizer is found, Mn-ZIF-8 has ray responsiveness, can continuously release Mn < 2 + > ions under X-ray irradiation, and can enhance the activation of a cGAS-STING signal channel so as to promote DCs maturation and antigen presentation, and enhance the T cell mediated immune response, such that the tumor treatment effect is enhanced. Furthermore, the invention provides the Mn-ZIF-8 microneedle, the microneedle has the characteristics of rapid dissolution and controlled release, ensures accurate delivery and continuous action of drugs at tumor sites, reduces systemic toxicity, and can significantly amplify local and systemic immune effects caused by radiotherapy and improve the therapeutic effect when used in combination with an immune checkpoint inhibitor.